References
- Bonn B, Leandersson C, Fontaine F, Zamora I. (2010). Enhanced metabolite identification with MS(E) and a semi-automated software for structural elucidation. Rapid Commun Mass Spectrom 24:3127–3138.
- Christrup LL. (1997). Morphine metabolites. Acta Anaesthesiol Scand 41:116–122.
- Clarke NJ, Rindgen D, Korfmacher WA, Cox KA. (2001). Systematic LC/MS metabolite identification in drug discovery. Anal Chem 73:430A–439A.
- Cone EJ, Darwin WD, Gorodetzky CW, Tan T. (1978). Comparative metabolism of hydrocodone in man, rat, guinea pig, rabbit, and dog. Drug Metab Dispos 6:488–493.
- Lelas S, Wegert S, Otton SV, Sellers EM, France CP. (1999). Inhibitors of cytochrome P450 differentially modify discriminative-stimulus and antinociceptive effects of hydrocodone and hydromorphone in rhesus monkeys. Drug Alcohol Depend 54:239–249.
- Li AC, Ding J, Jiang X, Denissen J. (2009). Two-injection workflow for a liquid chromatography/LTQ-Orbitrap system to complete in vivo biotransformation characterization: Demonstration with buspirone metabolite identification. Rapid Commun Mass Spectrom 23:3003–3012.
- Li AC, Yu E, Ring SC, Chovan JP. (2012). Identification of imine or enamine drug metabolites using online hydrogen/deuterium exchange and exact mass measurements. Rapid Commun Mass Spectrom 26:906–914.
- Lötsch J, Geisslinger G. (2001). Morphine-6-glucuronide: An analgesic of the future? Clin Pharmacokinet 40:485–499.
- Otton SV, Schadel M, Cheung SW, Kaplan HL, Busto UE, Sellers EM. (1993). CYP2D6 phenotype determines the metabolic conversion of hydrocodone to hydromorphone. Clin Pharmacol Ther 54:463–472.
- Prakash C, Shaffer CL, Nedderman A. (2007). Analytical strategies for identifying drug metabolites. Mass Spectrom Rev 26:340–369.
- Weston DJ, Weidolf L. (2012). Conference Report: High-resolution MS in drug discovery and development: Current applications and future perspectives. Bioanalysis 4:481–486.